The University of Chicago Header Logo

Connection

Richard Schilsky to Colorectal Neoplasms

Back to Details
This is a "connection" page, showing publications Richard Schilsky has written about Colorectal Neoplasms.
Richard Schilsky
Connection Strength
4.395
Colorectal Neoplasms
  1. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2022 Nov; 6:e2200191.
    View in: PubMed
    Score: 0.506
  2. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 10; 6:e2200306.
    View in: PubMed
    Score: 0.503
  3. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):743-750.
    View in: PubMed
    Score: 0.443
  4. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. J Oncol Pract. 2016 Feb; 12(2):180-1.
    View in: PubMed
    Score: 0.310
  5. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10; 34(2):179-85.
    View in: PubMed
    Score: 0.310
  6. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep; 12(9):553-60.
    View in: PubMed
    Score: 0.301
  7. First-line treatment options for patients with metastatic colorectal cancer. Nat Clin Pract Oncol. 2004 Dec; 1(2):70-1.
    View in: PubMed
    Score: 0.146
  8. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2004 Nov; 2(11):1-10; quiz 11-12.
    View in: PubMed
    Score: 0.145
  9. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7.
    View in: PubMed
    Score: 0.139
  10. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20; 41(33):5140-5150.
    View in: PubMed
    Score: 0.133
  11. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003 Mar 06; 348(10):883-90.
    View in: PubMed
    Score: 0.129
  12. Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation. Clin Colorectal Cancer. 2002 May; 2(1):51-2.
    View in: PubMed
    Score: 0.122
  13. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1519-26.
    View in: PubMed
    Score: 0.121
  14. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103.
    View in: PubMed
    Score: 0.116
  15. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001 Jul 12; 345(2):144-5; author reply 146.
    View in: PubMed
    Score: 0.115
  16. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000 Apr; 11(4):415-20.
    View in: PubMed
    Score: 0.106
  17. Immunotherapy for colorectal cancer. Curr Oncol Rep. 1999; 1(2):147-8.
    View in: PubMed
    Score: 0.097
  18. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45.
    View in: PubMed
    Score: 0.093
  19. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
    View in: PubMed
    Score: 0.087
  20. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J Clin Oncol. 2010 Feb 01; 28(4):527-30.
    View in: PubMed
    Score: 0.051
  21. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
    View in: PubMed
    Score: 0.045
  22. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004 Jun 01; 10(11):3908-18.
    View in: PubMed
    Score: 0.035
  23. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Clin Colorectal Cancer. 2002 Nov; 2(3):140-5.
    View in: PubMed
    Score: 0.032
  24. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002 Apr; 13(4):566-75.
    View in: PubMed
    Score: 0.030
  25. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
    View in: PubMed
    Score: 0.030
  26. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol. 2002 Jan; 13(1):87-91.
    View in: PubMed
    Score: 0.030
  27. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63.
    View in: PubMed
    Score: 0.028
  28. Pharmacology and clinical status of capecitabine. Oncology (Williston Park). 2000 Sep; 14(9):1297-306; discussion 1309-11.
    View in: PubMed
    Score: 0.027
  29. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2000 Aug; 18(15):2894-901.
    View in: PubMed
    Score: 0.027
  30. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
    View in: PubMed
    Score: 0.026
  31. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
    View in: PubMed
    Score: 0.023
  32. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs. 1998-1999; 16(3):275-8.
    View in: PubMed
    Score: 0.023
  33. Adjuvant therapy for colorectal cancer. Curr Probl Surg. 1997 Aug; 34(8):601-76.
    View in: PubMed
    Score: 0.022
  34. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996 Oct; 14(10):2674-81.
    View in: PubMed
    Score: 0.021
  35. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50.
    View in: PubMed
    Score: 0.018
  36. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.